Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients

HIV Medicine

Volumn 7, Issue 3, 2006, Pages 197-199

  Wateba, M I ^a   Billaud, E ^a   Dailly, Eric ^a   Jolliet, P ^a   Raffi, F ^a  

^a HÔTEL DIEU   (France)

Author keywords

Lopinavir; Therapeutic drug monitoring

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TENOFOVIR; VIRUS RNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUPERINFECTION; VIRUS LOAD;

ADULT; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33644752802     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00354.x     Document Type: Article

References (8)

1. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM. Therapeutic drug monitoring: An aid to optimising response to antiretroviral drugs? Drugs 2003; 63: 741-753.
2. Delaugerre C, Teglas JP, Treluyer JM et al. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ ritonavir. J Acquir Immune Defic Syndr 2004; 37: 1269-1275.
3. Gonzalez de Requena D, Gallego O, Valer L, Jimenez-Nacher I, Soriano V. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses 2004; 20: 275-278.
4. Taburet A, Garraffo R, Goujard C, Peytavin G, Treluyer JM. Pharmacologie des antirétroviraux, In: Delfraissy JF. ed. Prise en Charge des Personnes Infectées par le VIH. Recommandations du Groupe d'Experts. Paris, France, Médecine-Sciences Flammarion, 2004: 115-130.
5. Dailly E, Raffi F, Jolliet P. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. J Chromatogr B Anal Technol Biomed Life Sci 2004; 813: 353-358.
6. Delfraissy JF. Echecs thérapeutiques, In: Prise en Charge des Personnes Infectées par le VIH. Recommandations du Groupe d'Experts. Paris, France: Médecine-Sciences Flammarion, 2004: 79-94.
7. Poirier J, Zouai O, Meynard J, Girard P, Jaillon P. Inter-individual and intra-patient variabilities in lopinavir and ritonavir trough plasma concentration in HIV infected patients warrant therapautic drug monitoring. 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October-November 2004 [Abstract H-864].
8. Back D, Blaschke T, Boucher C et al. Optimising TDM in HIV Clinical Care-A Practical Guide to Performing Therapeutic Drug Monitoring for Antiretroviral Agents. Version 1, April 2003. http://www.Hivpharmacology.Com2005.